1. Search Result
Search Result
Isoforms Recommended: Kinesin-5/Eg5/KSP
Results for "

KSP

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

2

MCE Kits

3

Recombinant Proteins

1

Isotope-Labeled Compounds

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15187
    Filanesib
    Maximum Cited Publications
    7 Publications Verification

    ARRY-520

    Kinesin Apoptosis Cancer
    Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity .
    Filanesib
  • HY-50759
    Ispinesib
    Maximum Cited Publications
    7 Publications Verification

    SB-715992; CK-0238273

    Kinesin Apoptosis Cancer
    Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
    Ispinesib
  • HY-12069
    SB-743921 hydrochloride
    5 Publications Verification

    Kinesin Cancer
    SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM.
    SB-743921 hydrochloride
  • HY-50672

    Kinesin Apoptosis Lipoxygenase Cancer
    MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy .
    MK-0731
  • HY-13224

    Kinesin Apoptosis Mitosis Cancer
    AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity .
    AZD4877
  • HY-149416

    Drug-Linker Conjugates for ADC Cancer
    Mal-PEG8-Val-Ala-PAB-SB-743921 (Compound D7) is a Drug-Linker Conjugates for ADC. Mal-PEG8-Val-Ala-PAB-SB-743921 consists of KSP inhibitor SB-743921 (HY-14661) and a linker. Mal-PEG8-Val-Ala-PAB-SB-743921 can be used for synthesis of ADCs .
    Mal-PEG8-Val-Ala-PAB-SB-743921
  • HY-15187A

    (R)-ARRY-520

    Kinesin Cancer
    (R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC50 of 6 nM.
    (R)-Filanesib
  • HY-122247

    Kinesin Cancer
    PVZB1194 is a biphenyl-type inhibitor of Kinesin-5 ATPase activity that binds to the α4/α6 site of the motor domain in a nucleotide competitive manner. PVZB1194 has an IC50 of 0.12 μM for KSP ATPase. PVZB1194 induces mitotic arrest with the formation of a monopolar spindle, and inhibits HeLa cells proliferatio (IC50: 5.5 μM). PVZB1194 can be used in the study of tumors .
    PVZB1194
  • HY-14661

    Kinesin Cancer
    SB-743921 free base is a potent selective inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM. SB-743921 free base can induce mitotic arrest, block cell cycle progression, induce apoptosis, and can be used in the research of myeloma, leukemia and other diseases .
    SB-743921 free base
  • HY-171112

    Beta-lactamase Bacterial Infection
    KSP-1007 is a bicyclic boronate-based broad-spectrum β-lactamase inhibitor. KSP-1007 can effectively inhibit class A, B, C and D β-lactamases, including serine-type, metallo-type (such as NDM, VIM, IMP) and Acinetobacter baumannii OXA-type enzymes. KSP-1007 can enhance the antibacterial activity of Meropenem (HY-13678), reduce its MIC value, and be effective against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. KSP-1007 can be used for the research of bacterial infection .
    KSP-1007
  • HY-124790

    Kinesin Mitosis Cancer
    KSP-IA (compound 17) is a potent kinesin spindle protein (KSP) inhibitor with an IC50 value of 3.6 nM. KSP-IA inhibits cell mitosis .
    KSP-IA
  • HY-168727

    Kinesin Cancer
    KSP ligand 1 is a protein ligand that targets KSP (Kinesin), and it can be used to synthesize PROTAC KSP-IN-1 (HY-168725) for cancer research .
    KSP ligand 1
  • HY-168725

    PROTACs Kinesin Apoptosis Cancer
    PROTAC KSP degrader 1 (Compound 21) is a PROTAC Degrader for kinesin spindle protein (KSP), that degrades KSP in HCT-116 with DC50 of 114.8 nM. PROTAC KSP degrader 1 inhibits the proliferation of HCT-116 with IC50 of 10 nM, arrests the cell cycle of HCT-116 at G2/M phase, and induces apoptosis in HCT-116. PROTAC KSP degrader 1 exhibits antitumor efficacy in mouse model . (Blue: Ligand for E3 Ligase Cereblon (HY-103596); Blank: Linker (HY-168726); Pink: Target Protein Ligand (HY-168727))
    PROTAC KSP degrader 1
  • HY-177613A

    AD12115 sodium

    Kinesin Cancer
    ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
    ALN-12115 sodium
  • HY-177613

    AD12115

    Kinesin Cancer
    ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
    ALN-12115
  • HY-15187C
    Filanesib hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    ARRY-520 hydrochloride

    Kinesin Apoptosis Neurological Disease Cancer
    Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity .
    Filanesib hydrochloride
  • HY-157338

    ADC Linker Kinesin Cancer
    NHS-Ala-Ala-Asn-active metabolite is a cleavable antibody-drug conjugate (ADC) linker for synthesis of kinesin spindle protein (KSP)inhibitor .
    NHS-Ala-Ala-Asn-active metabolite
  • HY-122130

    MK-8267

    Kinesin Apoptosis Cancer
    SCH 2047069 (MK-8267) is an orally active kinesin spindle protein (KSP) inhibitor (Kd: 0.5 nM) that can cross the blood-brain barrier. SCH 2047069 exhibits an IC50 value of ≤ 5 nM against the KSP ATPase. SCH 2047069 exhibits broad-spectrum antitumor activity. SCH 2047069 can induce mitotic arrest and apoptosis in tumor cells. SCH 2047069 can be used in the research of tumors such as ovarian cancer, colon cancer, glioblastoma, and lymphoma .
    SCH 2047069
  • HY-177614

    AD3133 sodium

    VEGFR Cancer
    ALN-3133 sodium is a siRNA that targets VEGF, and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for kinesin spindle protein (KSP) and VEGF with potential antitumor activity.
    ALN-3133 sodium
  • HY-10084

    Kinesin Cancer
    CK0106023 is a potent and specific allosteric inhibitor of KSP with a Ki value of 12 nM, showing antitumor activity. CK0106023 causes mitotic arrest and growth inhibition in several tumor cell lines. CK0106023 exhibits antitumor activity in tumor-bearing mice .
    CK0106023
  • HY-15187B

    ARRY-520 TFA

    Kinesin Cancer
    Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity .
    Filanesib TFA
  • HY-50759A

    SB-715992 mesylate; CK-0238273 mesylate

    Kinesin Apoptosis Cancer
    Ispinesib (SB-715992) mesylate is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
    Ispinesib mesylate
  • HY-162292

    PI3K Kinesin Cancer
    Anticancer agent 190 (compound 3e) is an inhibitor targeting KSP (Kinesin) and PI3Kδ with activity against breast cancer .
    Anticancer agent 190
  • HY-50759R

    SB-715992 (Standard); CK-0238273 (Standard)

    Kinesin Apoptosis Reference Standards Cancer
    Ispinesib (Standard) is the analytical standard of Ispinesib. This product is intended for research and analytical applications. Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
    Ispinesib (Standard)
  • HY-50759S

    SB-715992-d5

    Kinesin Apoptosis Cancer
    Ispinesib-d5 (SB-715992-d5) is a deuterium labeled Ispinesib (HY-50759). Ispinesib is a specific inhibitor of kinesin spindle protein (KSP) .
    Ispinesib-d5
  • HY-117440

    Kinesin Cancer
    4'-Methoxy-S-trityl-L-cysteinol is an allosteric inhibitor of vertebrate Kinesin Spindle Protein (KSP). 4'-Methoxy-S-trityl-L-cysteinol significantly enhances its inhibitory activity against NCI60 tumor cells by modifying the trityl and cysteine groups. Its EC50 for bipolar spindle formation is 28 μM, showing stronger inhibitory potency than the parent molecule and monastrol.
    4'-Methoxy-S-trityl-L-cysteinol
  • HY-179355

    Kinesin Cancer
    KSP-IN-2 (compound 12) is a kinesin spindle protein (KSP) inhibitor with an IC50 of 450 nM .
    KSP-IN-1
  • HY-13224A

    Endogenous Metabolite Cancer
    AZD4877 hydrochloride is a synthetic dynein inhibitor with potential anti-tumor activity. AZD4877 selectively inhibits the microtubule dynein KSP (also known as kinesin-5 or Eg5), which may lead to inhibition of mitotic spindle assembly. The action of AZD4877 may activate the spindle assembly checkpoint, leading to cell cycle arrest at the mitotic stage. AZD4877 may induce cell death in actively dividing tumor cells. AZD4877 may be less likely to cause peripheral neuropathy associated with microtubule-targeted compounds as it is not involved in post-mitotic processes. AZD4877 is essential for the formation of bipolar spindles and the proper segregation of sister chromosomes .
    AZD4877 hydrochloride
  • HY-W198426

    Biphenyl-4-ylurea; (4-Phenylphenyl)urea

    Drug Derivative Others
    1-(-4-yl) urea (compound 44) is a biphenyl urea analog .
    1-([1,1'-Biphenyl]-4-yl)urea

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: